(RTTNews) -  Halozyme Therapeutics, Inc. (HALO: News ) revealed the insulin variability study results that demonstrated reduced intrasubject absorption variability for the combination of lispro, a meal time analog insulin, plus PH20, hyaluronidase, compared to subcutaneous injection of lispro alone.

When compared to lispro alone, the combination of lispro with PH20 reduced the variability for early and late insulin absorption, the time to maximum concentration, and the area under the curve at 15, 30, 60 and 120 minutes. The variability for maximum concentration was not affected. In addition, study results confirmed previously reported acceleration for both insulin absorption and action by coadministration of PH20.
In addition, Halozyme presented additional new data from the dose-ranging study first shown at the International Diabetes Federation Congress last month. These additional data again confirmed that PH20 at the optimized dose of 5 µg/100 U of insulin accelerated the absorption and action of insulin. Furthermore, PH20 improved the PK dose proportionality responses to prandial insulins across a range of physiologically relevant doses, including 2 to 20 U for insulin lispro and 6 to 24 U for human insulin.

Click here to receive FREE breaking news email alerts for Halozyme Therapeutics, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: contact editorial@rttnews.com